Stayble Therapeutics AB (publ)

DB:4K4 Stock Report

Market Cap: €1.8m

Stayble Therapeutics Management

Management criteria checks 2/4

Stayble Therapeutics' CEO is Andreas Gerward, appointed in Jan 2015, has a tenure of 9.92 years. directly owns 1.28% of the company’s shares, worth €22.76K. The average tenure of the management team and the board of directors is 8.9 years and 3.6 years respectively.

Key information

Andreas Gerward

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure9.9yrs
CEO ownership1.3%
Management average tenure8.9yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

CEO

Andreas Gerward (36 yo)

9.9yrs

Tenure

Mr. Andreas Gerward, M.Sc., is the Co-Founder and Chief Executive Officer of Stayble Therapeutics AB (publ) since 2015. Mr. Gerward joined Stayble Therapeutics AB in 2014. He has worked with pharmaceutical...

Leadership Team

NamePositionTenureCompensationOwnership
Andreas Gerward
Co-Founder & CEO9.9yrsno data1.28%
€ 22.8k
Mattias Munnich
Co-Founder7.9yrsno datano data
Erik Kullgren
Chief Financial Officerless than a yearno datano data
Anders Lehmann
Chief Scientific Officer9.9yrsno datano data

8.9yrs

Average Tenure

45yo

Average Age

Experienced Management: 4K4's management team is seasoned and experienced (8.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ulf Bjorklund
Chairman of the Board3.5yrsSEK 215.68kno data
Douglas Beall
Member of Scientific Advisory Board3.9yrsno datano data
Erik Kinnman
Director4.5yrsSEK 101.50kno data
Hans Meisel
Member of Scientific Advisory Board3.8yrsno datano data
Jane Laursen
Independent Director6.9yrsSEK 101.50kno data
Björn Strömqvist
Member of Scientific Advisory Boardno datano datano data
Gudrun Anstren
Independent Director3.5yrsSEK 101.50kno data
Gunnar Fernstrom
Independent Director3.5yrsSEK 101.50kno data
Daisuke Sakai
Member of Scientific Advisory Board1.3yrsno datano data

3.6yrs

Average Tenure

68yo

Average Age

Experienced Board: 4K4's board of directors are considered experienced (3.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 13:17
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Stayble Therapeutics AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution